[(2S,5R)-5-(2-氨基-9H-嘌呤-9-基)四氢呋喃-2-基]甲醇 | 107550-74-3

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 中文名称: [(2S,5R)-5-(2-氨基-9H-嘌呤-9-基)四氢呋喃-2-基]甲醇
• 英文名称: iso-2',3'-dideoxyadenosine
• 英文别名: 9-(2,3-dideoxy-β-D-erythro-pentofuranosyl)2-aminopurine；2-amino-9-(2,3-dideoxy-β-D-glycero-pentofuranosyl)-9H-purine；2-Amino-9-(beta-D-2,3-dideoxyribofuranosyl)purine；[(2S,5R)-5-(2-aminopurin-9-yl)oxolan-2-yl]methanol
• CAS: 107550-74-3
• 化学式: C₁₀H₁₃N₅O₂
• 分子量: 235.246
• InChiKey: HXUIKBBUGWIQMV-POYBYMJQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  17
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  99.1
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  [(2S,5R)-5-(2-氨基-9H-嘌呤-9-基)四氢呋喃-2-基]甲醇 在 N,N-二异丙基乙胺 作用下， 以 甲醇 、 水 、 N,N-二甲基甲酰胺 、 乙腈 为溶剂， 反应 37.25h， 生成 [[(2S,5R)-5-(2-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate;N,N-diethylethanamine
  参考文献：
  名称：

  非天然核苷二磷酸糖的合成

  摘要：

  最近，我们报道了一种合成多种天然核苷二磷酸 (NDP) 糖的有效化学方法。这种基于 cycloSal 方法的方法原则上也可用于制备稀有甚至非天然 NDP 糖。在此，介绍了含有磺基奎诺糖、葡萄糖-6-硫酸盐、L-半乳糖和 2-氟吡喃糖苷的 NDP 糖的合成，以及具有非天然核苷的 NDP 糖的合成。所描述的反应以高产率和短反应时间提供立体异构定义的 NDP 糖。

  DOI：

  10.1002/ejoc.201100906
• 作为产物：
  描述：

  2-氨基嘌呤 、 2',3'-二脱氧尿苷 反应 2.0h， 以44%的产率得到[(2S,5R)-5-(2-氨基-9H-嘌呤-9-基)四氢呋喃-2-基]甲醇
  参考文献：
  名称：

  Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides

  摘要：

  A series of 6-substituted 2',3'-dideoxypurine ribofuranosides (ddP) was enzymatically synthesized with live E. coli in an effort to enhance the lipophilicity of this class of anti-human immunodeficiency virus (HIV) compounds and thereby facilitate drug delivery into the central nervous system. All 6-halo-substituted ddPs were substantially more lipophilic, as defined by their octanol-water partition coefficient (P), than their nonhalogenated congeners 2',3'-dideoxyinosine (ddI) or 2',3'-dideoxyguanosine (ddG). For this class of compounds, log P's ranged from +0.5 to -1.2 in the following order: 6-iodo, 2-amino-6-iodo > 6-bromo, 2-amino-6-bromo > 6-chloro, 2-amino-6-chloro > 6-fluoro, 2-amino-6-fluoro >> ddG > ddI. These compounds were evaluated in vitro for ability to suppress the infectivity, replication, and cytopathic effect of HIV. 2-Amino-6-fluoro-, 2-amino-6-chloro-, and 6-fluoro-ddP exhibited a potent activity against HIV comparable to that of ddI or ddG and completely blocked the infectivity of HIV without affecting the growth of target cells. The comparative order of in vitro anti-HIV activity was 2-amino-6-fluoro, 2-amino-6-chloro, 6-fluoro > 2-amino-6-bromo > 2-amino-6-iodo, 6-chloro > 6-bromo > 6-iodo. These compounds also exhibited potent in vitro activity against HIV-2 and 3'-azido-3'-deoxythymidine-resistant HIV-1 variants. All 2-amino-6-halo-ddPs and 6-halo-ddPs were substrates for adenosine deaminase (ADA) and were converted to ddG or ddI, respectively. In the presence of the potent ADA inhibitor 2'-deoxycoformycin, 6-halo-substituted ddPs failed to exert an in vitro antiretroviral effect. These dideoxypurine nucleoside analogues represent a new class of lipophilic prodrugs of ddG and ddI that possess the potential for more effective therapy of HIV-induced neurologic disorders.

  DOI：

  10.1021/jm00109a012

文献信息

• Antiviral agents
  申请人：SYNTEX (U.S.A.) INC.

  公开号：EP0457326A1

  公开（公告）日：1991-11-21

  Nucleoside compounds of the formula wherein:    B is a purine or a pyrimidine;    X and X' are H, OH or F, provided that at least one is H;    Y and Y' are H, OH, OCH₃ or F, provided that at least one is H;    Y' and Z together form a cyclic phosphate ester, provided that Y is H; or Z is where n is zero, one, two or three; and Z' is N₃ or OCH₃;    provided that whenX' and Y' are OH and Z' is N₃, B is not cytosine, whenX' and Y' are OH and Z' is OCH₃, B is not uracil, adenine or cytosine, and whenZ' is N₃, X' is H, and Y' is H, OH, OCH₃, or F, B is not purine, cytosine, uracil, or thymine; and the pharmaceutically acceptable esters, ethers and salts thereof, have been found to have potent antiviral activity with a high therapeutic ratio.

  式中的核苷化合物 其中 B 是嘌呤或嘧啶； X 和 X'是 H、OH 或 F，但至少有一个是 H； Y 和 Y'是 H、OH、OCH₃ 或 F，但至少有一个是 H； Y' 和 Z 共同形成环磷酸酯，条件是 Y 是 H；或 Z 是 其中 n 为 0、1、2 或 3；以及 Z' 是 N₃ 或 OCH₃； 条件是 当 X' 和 Y' 为 OH 且 Z' 为 N₃ 时，B 不是胞嘧啶、 当X'和Y'为OH且Z'为OCH₃时，B不是尿嘧啶、腺嘌呤或胞嘧啶，以及 当 Z' 是 N₃，X' 是 H，Y' 是 H、OH、OCH₃ 或 F 时，B 不是嘌呤、胞嘧啶、尿嘧啶或胸腺嘧啶； 及其药学上可接受的酯、醚和盐，已被发现具有强效抗病毒活性和高治疗比。
• Hydrolysis of dideoxygenated purine nucleosides: effect of modification of the base moiety
  作者：Vasu Nair、Greg S. Buenger

  DOI：10.1021/jo00298a067

  日期：1990.5
• MURAKAMI, KUNICHIKA;SHIRASAKA, TAKUMA;YOSHIOKA, HIDETOSHI;KOJIMA, EIJI;AO+, J. MED. CHEM., 34,(1991) N, C. 1606-1612
  作者：MURAKAMI, KUNICHIKA、SHIRASAKA, TAKUMA、YOSHIOKA, HIDETOSHI、KOJIMA, EIJI、AO+

  DOI：——

  日期：——
• US5449664A
  申请人：——

  公开号：US5449664A

  公开（公告）日：1995-09-12